Description |
Ravoxertinib (GDC-0994) is an orally bioavailable ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
|
Target |
ERK1:6.1 nM (IC50)
ERK2:3.1 nM (IC50)
p-RSK:12 nM (IC50)
|
In Vitro |
Ravoxertinib (GDC-0994) also inhibits p90RSK with IC50 of 12 nM[1]. Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively[2].
|
In Vivo |
In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib (GDC-0994) is sufficient to achieve the desired target coverage for at least 8 h[1]. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice[2].
|
Animal Admin |
Mice[1] PK/PD data for Ravoxertinib (GDC-0994) in the HCT116 mouse xenograft model. HCT116 tumors are established in nude mice to a tumor volume of 400-600 mm3. Mice are treated with a single oral dose of 22 at 15, 30, or 100 mg/kg versus vehicle control alone (40% PEG400/60% (10% HPβCD)) follow by tumor and plasma collection at 2, 8, 16, and 24 h postdose. Tumor levels of phosphorylated p90RSK (pRSK) relative total p90RSK (tRSK) are measured by quantitative Western blot and are normalized to vehicle control at 2 h postdose (set to 100%). Plasma and tumor concentrations are measured by LC−MS.
|
Density | 1.5±0.1 g/cm3 |
Boiling Point | 734.6±70.0 °C at 760 mmHg |
Flash Point | 398.0±35.7 °C |
Exact Mass | 440.116394 |
PSA | 97.86000 |
LogP | 2.18 |
Vapour Pressure | 0.0±2.5 mmHg at 25°C |
Storage condition | -20℃ |